Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children

James R. Rodrigue, William Balistreri, Barbara Haber, Maureen M. Jonas, Parvathi Mohan, Jean Molleston, Karen F. Murray, Michael R. Narkewicz, Philip Rosenthal, Lesley J. Smith, Steven J. Lobritto, Kathleen B. Schwarz, Patricia R. Robuck, Bruce Barton, Regino P. González-Peralta

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The aim of this study was to prospectively assess the quality of life (QOL), behavioral/emotional functioning, and cognitive status of children undergoing treatment for hepatitis C virus (HCV) infection. In all, 114 children (5 to 18 years old) enrolled in a multisite randomized clinical trial (Peds-C) to evaluate peginterferon alpha 2a (PEG 2a) with ribavirin (RV) or with placebo (PL) completed several standardized measures prior to treatment and at 24 weeks, 48 weeks, 6 months following treatment, and at two annual follow-up visits. After 24 weeks of treatment, mean physical QOL scores declined significantly for both groups from baseline to 24 weeks of treatment (F = 5.8, P = 0.004), although scores remained in the average range. There were no significant time or group effects for behavioral/emotional or cognitive functioning. Three children (5%) in the PEG 2a + RV group and no children in the PEG 2a + PL group had a clinically significant increase in depression symptoms. For those children who received 48 weeks of treatment, there were no significant time or group effects on any of the outcome measures (P > 0.05). A majority of children in both the PEG 2a + RV and PEG 2a + PL groups experienced no clinically significant change in physical QOL, behavioral adjustment, depression, or cognitive functioning during or after treatment. Conclusion: Overall QOL and psychosocial functioning are not deleteriously impacted by PEG 2a + RV or PL treatment of children with HCV.

Original languageEnglish
Pages (from-to)1468-1475
Number of pages8
JournalHepatology
Volume53
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

Ribavirin
Quality of Life
Placebos
Therapeutics
Hepacivirus
Virus Diseases
peginterferon alfa-2a
Randomized Controlled Trials
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Hepatology

Cite this

Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children. / Rodrigue, James R.; Balistreri, William; Haber, Barbara; Jonas, Maureen M.; Mohan, Parvathi; Molleston, Jean; Murray, Karen F.; Narkewicz, Michael R.; Rosenthal, Philip; Smith, Lesley J.; Lobritto, Steven J.; Schwarz, Kathleen B.; Robuck, Patricia R.; Barton, Bruce; González-Peralta, Regino P.

In: Hepatology, Vol. 53, No. 5, 05.2011, p. 1468-1475.

Research output: Contribution to journalArticle

Rodrigue, JR, Balistreri, W, Haber, B, Jonas, MM, Mohan, P, Molleston, J, Murray, KF, Narkewicz, MR, Rosenthal, P, Smith, LJ, Lobritto, SJ, Schwarz, KB, Robuck, PR, Barton, B & González-Peralta, RP 2011, 'Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children', Hepatology, vol. 53, no. 5, pp. 1468-1475. https://doi.org/10.1002/hep.24248
Rodrigue, James R. ; Balistreri, William ; Haber, Barbara ; Jonas, Maureen M. ; Mohan, Parvathi ; Molleston, Jean ; Murray, Karen F. ; Narkewicz, Michael R. ; Rosenthal, Philip ; Smith, Lesley J. ; Lobritto, Steven J. ; Schwarz, Kathleen B. ; Robuck, Patricia R. ; Barton, Bruce ; González-Peralta, Regino P. / Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children. In: Hepatology. 2011 ; Vol. 53, No. 5. pp. 1468-1475.
@article{708502544b58406495956df30449e0fa,
title = "Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children",
abstract = "The aim of this study was to prospectively assess the quality of life (QOL), behavioral/emotional functioning, and cognitive status of children undergoing treatment for hepatitis C virus (HCV) infection. In all, 114 children (5 to 18 years old) enrolled in a multisite randomized clinical trial (Peds-C) to evaluate peginterferon alpha 2a (PEG 2a) with ribavirin (RV) or with placebo (PL) completed several standardized measures prior to treatment and at 24 weeks, 48 weeks, 6 months following treatment, and at two annual follow-up visits. After 24 weeks of treatment, mean physical QOL scores declined significantly for both groups from baseline to 24 weeks of treatment (F = 5.8, P = 0.004), although scores remained in the average range. There were no significant time or group effects for behavioral/emotional or cognitive functioning. Three children (5{\%}) in the PEG 2a + RV group and no children in the PEG 2a + PL group had a clinically significant increase in depression symptoms. For those children who received 48 weeks of treatment, there were no significant time or group effects on any of the outcome measures (P > 0.05). A majority of children in both the PEG 2a + RV and PEG 2a + PL groups experienced no clinically significant change in physical QOL, behavioral adjustment, depression, or cognitive functioning during or after treatment. Conclusion: Overall QOL and psychosocial functioning are not deleteriously impacted by PEG 2a + RV or PL treatment of children with HCV.",
author = "Rodrigue, {James R.} and William Balistreri and Barbara Haber and Jonas, {Maureen M.} and Parvathi Mohan and Jean Molleston and Murray, {Karen F.} and Narkewicz, {Michael R.} and Philip Rosenthal and Smith, {Lesley J.} and Lobritto, {Steven J.} and Schwarz, {Kathleen B.} and Robuck, {Patricia R.} and Bruce Barton and Gonz{\'a}lez-Peralta, {Regino P.}",
year = "2011",
month = "5",
doi = "10.1002/hep.24248",
language = "English",
volume = "53",
pages = "1468--1475",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children

AU - Rodrigue, James R.

AU - Balistreri, William

AU - Haber, Barbara

AU - Jonas, Maureen M.

AU - Mohan, Parvathi

AU - Molleston, Jean

AU - Murray, Karen F.

AU - Narkewicz, Michael R.

AU - Rosenthal, Philip

AU - Smith, Lesley J.

AU - Lobritto, Steven J.

AU - Schwarz, Kathleen B.

AU - Robuck, Patricia R.

AU - Barton, Bruce

AU - González-Peralta, Regino P.

PY - 2011/5

Y1 - 2011/5

N2 - The aim of this study was to prospectively assess the quality of life (QOL), behavioral/emotional functioning, and cognitive status of children undergoing treatment for hepatitis C virus (HCV) infection. In all, 114 children (5 to 18 years old) enrolled in a multisite randomized clinical trial (Peds-C) to evaluate peginterferon alpha 2a (PEG 2a) with ribavirin (RV) or with placebo (PL) completed several standardized measures prior to treatment and at 24 weeks, 48 weeks, 6 months following treatment, and at two annual follow-up visits. After 24 weeks of treatment, mean physical QOL scores declined significantly for both groups from baseline to 24 weeks of treatment (F = 5.8, P = 0.004), although scores remained in the average range. There were no significant time or group effects for behavioral/emotional or cognitive functioning. Three children (5%) in the PEG 2a + RV group and no children in the PEG 2a + PL group had a clinically significant increase in depression symptoms. For those children who received 48 weeks of treatment, there were no significant time or group effects on any of the outcome measures (P > 0.05). A majority of children in both the PEG 2a + RV and PEG 2a + PL groups experienced no clinically significant change in physical QOL, behavioral adjustment, depression, or cognitive functioning during or after treatment. Conclusion: Overall QOL and psychosocial functioning are not deleteriously impacted by PEG 2a + RV or PL treatment of children with HCV.

AB - The aim of this study was to prospectively assess the quality of life (QOL), behavioral/emotional functioning, and cognitive status of children undergoing treatment for hepatitis C virus (HCV) infection. In all, 114 children (5 to 18 years old) enrolled in a multisite randomized clinical trial (Peds-C) to evaluate peginterferon alpha 2a (PEG 2a) with ribavirin (RV) or with placebo (PL) completed several standardized measures prior to treatment and at 24 weeks, 48 weeks, 6 months following treatment, and at two annual follow-up visits. After 24 weeks of treatment, mean physical QOL scores declined significantly for both groups from baseline to 24 weeks of treatment (F = 5.8, P = 0.004), although scores remained in the average range. There were no significant time or group effects for behavioral/emotional or cognitive functioning. Three children (5%) in the PEG 2a + RV group and no children in the PEG 2a + PL group had a clinically significant increase in depression symptoms. For those children who received 48 weeks of treatment, there were no significant time or group effects on any of the outcome measures (P > 0.05). A majority of children in both the PEG 2a + RV and PEG 2a + PL groups experienced no clinically significant change in physical QOL, behavioral adjustment, depression, or cognitive functioning during or after treatment. Conclusion: Overall QOL and psychosocial functioning are not deleteriously impacted by PEG 2a + RV or PL treatment of children with HCV.

UR - http://www.scopus.com/inward/record.url?scp=79955085510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955085510&partnerID=8YFLogxK

U2 - 10.1002/hep.24248

DO - 10.1002/hep.24248

M3 - Article

C2 - 21351116

AN - SCOPUS:79955085510

VL - 53

SP - 1468

EP - 1475

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -